One goal is to complete the registration of IMVAMUNE(R). The vaccine will then be commercialized via sales to the United States and other countries.
In addition, the intention is to build up a biodefense portfolio of projects that can complement IMVAMUNE(R) and ensure the Company a sustained and growing business.
As part of building up this portfolio, Bavarian Nordic has initiated a preclinical program for an anthrax vaccine. The Company sees a number of synergies - both in the development and in market approach which support the development of such a vaccine. Also, it is expected that a combined anthrax and smallpox vaccine can be developed and thus Bavarian Nordic would be able to offer one vaccine against two of the top biological threats. The anthrax program is expected to enter Phase I in 2008.
In the short term, the goal is to complete the Phase I/II studies of the vaccine candidate for breast cancer and to initiate Phase I/II studies of the vaccine candidate for prostate cancer.
As and when positive clinical data are obtained, partnering of the projects will be considered and the Company will also keep an eye on potential in-licensing opportunities.
The cancer business area has been given a higher priority and it is the Company's goal to expand the cancer portfolio. Later in 2008 the Company expects to announce initiatives to strengthen this area.
The Company has a number of projects in infectious diseases, all of
which are at an early development stage: HIV, measles and RSV, dengue fever
and Japanese encephalitis. The goal with the first two projects is to
complete early-stage clinical trials. If supported by the data obtained,
the option of placing these projects in external partnerships will be
explored. Alternatively, the Company will seek other external funding. For
the latter two projects, discussions with a potential externa
|SOURCE Bavarian Nordic A/S|
Copyright©2008 PR Newswire.
All rights reserved